Long-term care patients with dysphagia do not always have FDA-approved liquid suspensions available. When tablets are crushed or compounded, the formulations can put them in danger, as the dosing consistency and efficacy can change.
Attendees will learn about this and more at an April 2 webinar, which begins at 1 p.m. ET.
Albert Riddle, M.D., President and CEO of Riddle Medical Group, will present on FDA guidelines and how providers can better understand dysphagia. Senior Editor Elizabeth Newman will moderate the event.
Click here to register.
